TKIlääkkeistä

TKIlääkkeet, also known as TK medicine, refers to medicines that are eligible for reimbursement under the Finnish national health insurance system, administered by Kela. The purpose of TKIlääkkeet is to make essential medications more affordable for the public.

For a medicine to be classified as a TKIlääke, it must meet specific criteria set by the Finnish Medicines Agency (Fimea) and Kela. These criteria typically relate to the medical necessity and effectiveness of the drug, as well as its cost-effectiveness compared to alternative treatments. The reimbursement is usually a partial refund of the purchase price, with the patient paying the remainder.

The list of TKIlääkkeet is extensive and covers a wide range of therapeutic areas, including treatments for chronic diseases, infections, and pain management. Patients can obtain information about which specific medications are reimbursed and the extent of the reimbursement by consulting their doctor, pharmacist, or Kela's official publications.

The reimbursement system for TKIlääkkeet is a key component of the Finnish healthcare model, aiming to ensure equitable access to necessary medical treatments for all residents. The system is regularly reviewed and updated to reflect advancements in medical knowledge and the availability of new pharmaceuticals.